JP2006526031A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006526031A5 JP2006526031A5 JP2006519178A JP2006519178A JP2006526031A5 JP 2006526031 A5 JP2006526031 A5 JP 2006526031A5 JP 2006519178 A JP2006519178 A JP 2006519178A JP 2006519178 A JP2006519178 A JP 2006519178A JP 2006526031 A5 JP2006526031 A5 JP 2006526031A5
- Authority
- JP
- Japan
- Prior art keywords
- represented
- pharmaceutically acceptable
- pharmaceutical composition
- acceptable salt
- following formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003148073 | 2003-05-26 | ||
| PCT/JP2004/007562 WO2004103369A1 (en) | 2003-05-26 | 2004-05-26 | Pharmaceutical composition containing histone deacetylase inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006526031A JP2006526031A (ja) | 2006-11-16 |
| JP2006526031A5 true JP2006526031A5 (enExample) | 2006-12-28 |
Family
ID=33475383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006519178A Pending JP2006526031A (ja) | 2003-05-26 | 2004-05-26 | ヒストンデアセチラーゼ阻害物質を含む医薬組成物 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20070098816A1 (enExample) |
| EP (1) | EP1626719A1 (enExample) |
| JP (1) | JP2006526031A (enExample) |
| KR (1) | KR100938712B1 (enExample) |
| CN (2) | CN1794991A (enExample) |
| AR (1) | AR045318A1 (enExample) |
| AU (1) | AU2004241873C1 (enExample) |
| BR (1) | BRPI0410959A (enExample) |
| CA (4) | CA2527191A1 (enExample) |
| CL (1) | CL2004001278A1 (enExample) |
| CO (1) | CO5660262A2 (enExample) |
| CR (1) | CR8163A (enExample) |
| CU (1) | CU23490B7 (enExample) |
| EC (1) | ECSP056253A (enExample) |
| IL (1) | IL171941A0 (enExample) |
| ME (1) | MEP32308A (enExample) |
| MX (1) | MXPA05012345A (enExample) |
| NO (1) | NO20055417L (enExample) |
| NZ (1) | NZ543591A (enExample) |
| PE (1) | PE20050206A1 (enExample) |
| RS (1) | RS20050884A (enExample) |
| RU (1) | RU2322971C2 (enExample) |
| TW (1) | TW200505424A (enExample) |
| UA (1) | UA81499C2 (enExample) |
| UY (1) | UY28330A1 (enExample) |
| WO (1) | WO2004103369A1 (enExample) |
| ZA (1) | ZA200509515B (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
| US20030129724A1 (en) | 2000-03-03 | 2003-07-10 | Grozinger Christina M. | Class II human histone deacetylases, and uses related thereto |
| US7244853B2 (en) | 2001-05-09 | 2007-07-17 | President And Fellows Of Harvard College | Dioxanes and uses thereof |
| US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US7375228B2 (en) | 2003-03-17 | 2008-05-20 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| DE602004027824D1 (de) | 2003-09-25 | 2010-08-05 | Astellas Pharma Inc | Antitumorales mittel mit einem histon-deacetylase-hemmer und einem topoisomerase-ii-hemmer |
| EP1712552A1 (en) * | 2005-04-11 | 2006-10-18 | INDENA S.p.A. | Semisynthesis process for the preparation of 10-deacetyl-n-debenzoyl-paclitaxel |
| US7446126B2 (en) * | 2004-10-08 | 2008-11-04 | Indena S.P.A. | Semisynthesis process for the preparation of 10-deacetyl-N-debenzoyl-paclitaxel |
| US7642275B2 (en) | 2004-12-16 | 2010-01-05 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| JP2008533053A (ja) * | 2005-03-11 | 2008-08-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド | ヒストン脱アセチル化酵素阻害剤は、がん細胞を上皮増殖因子受容体阻害剤に対して感受性にする |
| SG171690A1 (en) | 2005-03-22 | 2011-06-29 | Harvard College | Treatment of protein degradation disorders |
| JP2008540574A (ja) | 2005-05-11 | 2008-11-20 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
| CA2615105A1 (en) | 2005-07-14 | 2007-01-25 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| WO2008091349A1 (en) | 2006-02-14 | 2008-07-31 | The President And Fellows Of Harvard College | Bifunctional histone deacetylase inhibitors |
| DK2010168T3 (da) | 2006-02-14 | 2014-07-21 | Harvard College | Histondeacetylase-inhibitore |
| WO2007130429A2 (en) | 2006-05-03 | 2007-11-15 | The President And Fellows Of Harvard College | Histone deacetylase and tubulin deacetylase inhibitors |
| GB0625283D0 (en) * | 2006-12-19 | 2007-01-24 | Cyclacel Ltd | Combination |
| PT2099442E (pt) * | 2006-12-26 | 2015-02-10 | Pharmacyclics Inc | Métodos de utilização de inibidores de histona desacetilase e monitorização de biomarcadores em terapia de combinação |
| WO2009067453A1 (en) * | 2007-11-19 | 2009-05-28 | Syndax Pharmaceuticals, Inc. | Combinations of hdac inhibitors and proteasome inhibitors |
| US8293513B2 (en) * | 2007-12-14 | 2012-10-23 | Georgetown University | Histone deacetylase inhibitors |
| EP2321264B1 (en) | 2008-07-23 | 2016-05-04 | President and Fellows of Harvard College | Deacetylase inhibitors and uses thereof |
| GB2462893B (en) * | 2008-08-29 | 2010-10-13 | Bayer Schering Pharma Ag | N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B |
| RS52164B (sr) * | 2008-08-29 | 2012-08-31 | Bayer Pharma Aktiengesellschaft | N-(2-aminofenil)-4-[n-(piridin-3-il)-metoksikarbonilaminometil]-benzamid (ms-275)polimorf b |
| PL3354650T3 (pl) | 2008-12-19 | 2022-06-13 | Vertex Pharmaceuticals Incorporated | Związki przydatne jako inhibitory kinazy atr |
| US20120034302A1 (en) * | 2009-02-11 | 2012-02-09 | Liangping Yu | Particulate composition and the method of making the same |
| WO2010125462A2 (en) * | 2009-05-01 | 2010-11-04 | Oncozyme Pharma Inc. | Pentamidine combinations for treating cancer |
| CA2763786C (en) * | 2009-06-08 | 2014-09-30 | Gilead Sciences, Inc. | Alkanoylamino benzamide aniline hdac inihibitor compounds |
| US8716344B2 (en) | 2009-08-11 | 2014-05-06 | President And Fellows Of Harvard College | Class- and isoform-specific HDAC inhibitors and uses thereof |
| BR112012004149A2 (pt) * | 2009-08-25 | 2016-03-22 | Abraxis Bioscience Llc | terapia de combinação com composições de nanopartículas de taxano e inibidores de hedgehog |
| JP5836367B2 (ja) | 2010-05-12 | 2015-12-24 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| UA110853C2 (uk) | 2011-09-13 | 2016-02-25 | Фармасайклікс, Інк. | Лікарські форми інгібітора гістондеацетилази у комбінації з бендамустином та їхнє застосування |
| AU2012315384B2 (en) | 2011-09-30 | 2017-08-10 | Vertex Pharmaceuticals Incorporated | Treating pancreatic cancer and non-small cell lung cancer with ATR inhibitors |
| RU2018147217A (ru) | 2011-09-30 | 2019-01-18 | Вертекс Фармасьютикалз Инкорпорейтед | Способы получения соединений, которые можно использовать в качестве ингибиторов киназы atr |
| WO2013085902A1 (en) * | 2011-12-05 | 2013-06-13 | The University Of Texas M.D. | Combination therapy methods for treating an inflammatory breast cancer |
| CN104582795B (zh) | 2012-04-05 | 2018-04-20 | 沃泰克斯药物股份有限公司 | 可用作atr激酶抑制剂的化合物及其组合疗法 |
| DK2904406T3 (en) | 2012-10-04 | 2018-06-18 | Vertex Pharma | METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE |
| JP6320506B2 (ja) | 2013-03-12 | 2018-05-09 | セルジーン クオンティセル リサーチ，インク． | ヒストンデメチラーゼ阻害剤 |
| US9963452B2 (en) * | 2013-03-14 | 2018-05-08 | Augusta Pharmaceuticals Inc. | Methods, compounds, and compositions for inhibition of ROS |
| EA201592012A8 (ru) * | 2014-02-21 | 2018-10-31 | Общество С Ограниченной Ответственностью "Биолаб 612" | Применение флагеллина для улучшенной химиотерапии |
| SG11201702119PA (en) | 2014-09-17 | 2017-04-27 | Quanticel Pharmaceuticals Inc | Histone demethylase inhibitors |
| US11464774B2 (en) | 2015-09-30 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| US11596612B1 (en) | 2022-03-08 | 2023-03-07 | PTC Innovations, LLC | Topical anesthetics |
| WO2025041160A1 (en) * | 2023-08-19 | 2025-02-27 | Birla Institute Of Technology And Science (Bits), Pilani | Bifunctional conjugate molecules for cancer treatment and process of making the same |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
| US6794392B1 (en) * | 1996-09-30 | 2004-09-21 | Schering Aktiengesellschaft | Cell differentiation inducer |
| US6174905B1 (en) * | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
| JP3354090B2 (ja) * | 1996-09-30 | 2002-12-09 | シエーリング アクチエンゲゼルシャフト | 分化誘導剤 |
| US5753637A (en) * | 1996-10-09 | 1998-05-19 | Ideal Ideas, Inc. | Method of treating acne conditions |
| PT1115391E (pt) * | 1998-09-25 | 2003-02-28 | Warner Lambert Co | Quimioterapia do cancro com acetildinalina em combinacao com gemcitabina capecitabina ou cisplatina |
| AU4144400A (en) * | 1999-04-27 | 2000-11-10 | Mitsubishi Pharma Corporation | Preventives/remedies for liver diseases |
| IL149363A0 (en) * | 1999-11-10 | 2002-11-10 | Warner Lambert Co | Combination chemotherapy |
| US6905669B2 (en) * | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| CZ20022216A3 (cs) * | 2001-07-02 | 2003-05-14 | Warner-Lambert Company | Kombinační chemoterapie |
| JP2003137866A (ja) * | 2001-11-01 | 2003-05-14 | Sankyo Co Ltd | フェニレンジアミン誘導体 |
-
2004
- 2004-05-25 PE PE2004000533A patent/PE20050206A1/es not_active Application Discontinuation
- 2004-05-26 ME MEP-323/08A patent/MEP32308A/xx unknown
- 2004-05-26 MX MXPA05012345A patent/MXPA05012345A/es active IP Right Grant
- 2004-05-26 RS YUP-2005/0884A patent/RS20050884A/sr unknown
- 2004-05-26 CN CNA2004800146332A patent/CN1794991A/zh active Pending
- 2004-05-26 CL CL200401278A patent/CL2004001278A1/es unknown
- 2004-05-26 UY UY28330A patent/UY28330A1/es not_active Application Discontinuation
- 2004-05-26 WO PCT/JP2004/007562 patent/WO2004103369A1/en not_active Ceased
- 2004-05-26 CN CNA2008101007303A patent/CN101322707A/zh active Pending
- 2004-05-26 KR KR1020057022615A patent/KR100938712B1/ko not_active Expired - Fee Related
- 2004-05-26 AU AU2004241873A patent/AU2004241873C1/en not_active Ceased
- 2004-05-26 EP EP04734923A patent/EP1626719A1/en not_active Withdrawn
- 2004-05-26 CA CA002527191A patent/CA2527191A1/en not_active Abandoned
- 2004-05-26 US US10/558,208 patent/US20070098816A1/en not_active Abandoned
- 2004-05-26 AR ARP040101807A patent/AR045318A1/es not_active Application Discontinuation
- 2004-05-26 TW TW093114934A patent/TW200505424A/zh unknown
- 2004-05-26 JP JP2006519178A patent/JP2006526031A/ja active Pending
- 2004-05-26 CA CA002634709A patent/CA2634709A1/en not_active Abandoned
- 2004-05-26 NZ NZ543591A patent/NZ543591A/en unknown
- 2004-05-26 UA UAA200512454A patent/UA81499C2/xx unknown
- 2004-05-26 RU RU2005140570/15A patent/RU2322971C2/ru active IP Right Revival
- 2004-05-26 CA CA002634766A patent/CA2634766A1/en not_active Abandoned
- 2004-05-26 CA CA002634765A patent/CA2634765A1/en not_active Abandoned
- 2004-05-26 BR BRPI0410959-7A patent/BRPI0410959A/pt not_active IP Right Cessation
-
2005
- 2005-11-14 IL IL171941A patent/IL171941A0/en unknown
- 2005-11-16 NO NO20055417A patent/NO20055417L/no not_active Application Discontinuation
- 2005-11-24 ZA ZA200509515A patent/ZA200509515B/en unknown
- 2005-11-25 CU CU20050237A patent/CU23490B7/es not_active IP Right Cessation
- 2005-12-22 CO CO05129159A patent/CO5660262A2/es unknown
- 2005-12-26 EC EC2005006253A patent/ECSP056253A/es unknown
-
2006
- 2006-01-02 CR CR8163A patent/CR8163A/es not_active Application Discontinuation